Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BMEA NASDAQ:PTGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.29-3.0%$1.34$0.87▼$2.99$96.16M-0.31947,407 shs722,114 shsPTGXProtagonist Therapeutics$131.27+1.1%$111.38$50.49▼$141.10$8.35B1.79907,137 shs564,975 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion-3.01%-7.86%+10.26%-34.52%-33.51%PTGXProtagonist Therapeutics+1.06%-6.80%+19.58%+24.50%+137.68%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBMEABiomea Fusion$1.29-3.0%$1.34$0.87▼$2.99$96.16M-0.31947,407 shs722,114 shsPTGXProtagonist Therapeutics$131.27+1.1%$111.38$50.49▼$141.10$8.35B1.79907,137 shs564,975 shsOptions Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBMEABiomea Fusion-3.01%-7.86%+10.26%-34.52%-33.51%PTGXProtagonist Therapeutics+1.06%-6.80%+19.58%+24.50%+137.68%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBMEABiomea Fusion 2.75Moderate Buy$8.50558.91% UpsidePTGXProtagonist Therapeutics 2.94Moderate Buy$119.21-9.18% DownsideCurrent Analyst Ratings BreakdownLatest BMEA and PTGX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/14/2026PTGXProtagonist Therapeutics BarclaysSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOverweight$119.00 ➝ $151.007/8/2026PTGXProtagonist Therapeutics Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy7/7/2026PTGXProtagonist Therapeutics Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$121.00 ➝ $145.007/1/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/1/2026PTGXProtagonist Therapeutics TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy6/16/2026BMEABiomea Fusion Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$135.005/21/2026PTGXProtagonist Therapeutics Wolfe ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$135.005/15/2026PTGXProtagonist Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D+)5/6/2026PTGXProtagonist Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingNeutral$110.005/6/2026PTGXProtagonist Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform(Data available from 7/15/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBMEABiomea FusionN/AN/AN/AN/A$0.42 per shareN/APTGXProtagonist Therapeutics$46.02M183.44N/AN/A$9.83 per share13.35Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBMEABiomea Fusion-$61.80M-$0.68N/AN/AN/AN/A-265.37%-103.96%8/4/2026 (Estimated)PTGXProtagonist Therapeutics-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)Latest BMEA and PTGX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2026Q2 2026PTGXProtagonist Therapeutics$2.11N/AN/AN/A$190.30 millionN/A8/4/2026Q2 2026BMEABiomea Fusion-$0.21N/AN/AN/AN/AN/A5/11/2026Q1 2026BMEABiomea Fusion-$0.24-$0.17+$0.07-$0.17N/AN/A5/5/2026Q1 2026PTGXProtagonist Therapeutics-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthBMEABiomea FusionN/AN/AN/AN/AN/APTGXProtagonist TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBMEABiomea FusionN/A4.984.98PTGXProtagonist TherapeuticsN/A17.7617.76Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBMEABiomea Fusion96.72%PTGXProtagonist Therapeutics98.63%Insider OwnershipCompanyInsider OwnershipBMEABiomea Fusion10.60%PTGXProtagonist Therapeutics5.19%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBMEABiomea Fusion5072.30 million64.64 millionOptionablePTGXProtagonist Therapeutics12064.31 million60.97 millionOptionableBMEA and PTGX HeadlinesRecent News About These CompaniesBest Momentum Stocks to Buy for July 13thJuly 13 at 11:01 AM | zacks.comNew Strong Buy Stocks for July 13thJuly 13 at 4:26 AM | zacks.comProtagonist Therapeutics (NASDAQ:PTGX) Raised to Strong-Buy at Zacks ResearchJuly 10, 2026 | marketbeat.comProtagonist Therapeutics (PTGX) Stock Still Looks Stretched After FDA Priority ReviewJuly 9, 2026 | finance.yahoo.comProtagonist Therapeutics (PTGX) After Icotyde Launch And Rusfertide Review Looks UndervaluedJuly 9, 2026 | finance.yahoo.comNew Strong Buy Stocks for July 9thJuly 9, 2026 | zacks.comProtagonist Therapeutics (PTGX) Is Up 12.5% After Rusfertide Priority Review Focus - Has The Bull Case Changed?July 8, 2026 | finance.yahoo.comProtagonist Therapeutics (PTGX) Surges 7.1%: Is This an Indication of Further Gains?July 8, 2026 | zacks.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Johnson & Johnson (JNJ) and Protagonist Therapeutics (PTGX)July 8, 2026 | theglobeandmail.comWhy Protagonist Therapeutics, Inc.’s (PTGX) Stock Is Up 5.03%July 7, 2026 | aaii.comAPTGX Stock Surges 64% in Six Months: What Is Driving the Rally?July 7, 2026 | zacks.comProtagonist Therapeutics (NASDAQ:PTGX) Given New $145.00 Price Target at Truist FinancialJuly 7, 2026 | americanbankingnews.comProtagonist Therapeutics (NASDAQ:PTGX) Price Target Raised to $145.00 at Truist FinancialJuly 7, 2026 | marketbeat.comWhy Wall Street’s wrong for loving Protagonist Therapeutics stockJuly 2, 2026 | msn.comProtagonist Therapeutics Reports Granting of Inducement AwardsJuly 1, 2026 | accessnewswire.comAPictet Asset Management Holding SA Boosts Stock Position in Protagonist Therapeutics, Inc. $PTGXJune 30, 2026 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Reaches New 52-Week High - Should You Buy?June 29, 2026 | marketbeat.comLouisiana State Employees Retirement System Makes New $2.75 Million Investment in Protagonist Therapeutics, Inc. $PTGXJune 29, 2026 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Lowered to "Buy" Rating by Wall Street ZenJune 27, 2026 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Director William Waddill Sells 9,000 SharesJune 26, 2026 | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Recommendation of "Moderate Buy" from AnalystsJune 24, 2026 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeBMEA and PTGX Company DescriptionsBiomea Fusion NASDAQ:BMEA$1.29 -0.04 (-3.01%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$1.29 0.00 (-0.31%) As of 05:22 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.Protagonist Therapeutics NASDAQ:PTGX$131.27 +1.38 (+1.06%) Closing price 07/14/2026 04:00 PM EasternExtended Trading$133.60 +2.33 (+1.78%) As of 04:57 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Why Fastenal’s Latest Drop Could Be Its Biggest Opportunity Yet 3 Overlooked Energy ETFs Delivering Strong Returns and Income 3 Space Stocks That Could Outshine SpaceX After Its IPO 3 Energy Stocks Racing to Fix AI's Power Problem JPMorgan’s Q2 Strength Gives the Stock Rally New Support No Space For Panic: T-Mobile Shrugs Off The Starlink Threat Prepare for the Next Wave of Factory Automation With These 3 Standout Names Wedbush Pounds the Table—Buy Sandisk Before August 5 Earnings Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
